SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kuter, D. J. Articles by McCullough, J. Search for Related Content PubMed PubMed Citation Articles by Kuter, D. J. Articles by McCullough, J. Related Collections Transfusion Medicine Clinical Trials and Observations Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 September 2001, Vol. 98, No. 5, pp. 1339-1345 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Thrombopoietin therapy increases platelet yields in healthy platelet donors David J. Kuter, Lawrence T. Goodnough, John Romo, John DiPersio, Randolph Peterson, Dianne Tomita, William Sheridan, and Jeffrey McCullough From Massachusetts General Hospital, Boston; Washington University, St Louis, MO; University of Minnesota, Minneapolis; and Amgen, Thousand Oaks, CA. The recombinant thrombopoietins have been shown to be effective stimulators of platelet production in cancer patients. It was therefore of interest to determine if one of these, pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), could be used to increase platelet counts and consequently platelet yields from apheresis in healthy platelet donors. In a blinded, 2-cycle, crossover study, 59 platelet donors were randomized to receive a single subcutaneous injection of PEG-rHuMGDF (1 µg/kg or 3 µg/kg) or placebo and 15 days later undergo platelet apheresis. Donors treated with placebo had a median peak platelet count after PEG-rHuMGDF injection of 248 × 109/L compared with 366 × 109/L in donors treated with 1 µg/kg PEG-rHuMGDF and 602 × 109/L in donors treated with 3 µg/kg PEG-rHuMGDF. The median maximum percentage that platelet counts increased from baseline was 10% in donors who received placebo compared with 70% in donors who received 1 µg/kg and 167% in donors who received 3 µg/kg PEG-rHuMGDF. There was a direct relationship between the platelet yield and the preapheresis platelet count: Placebo-treated donors provided 3.8 × 1011 (range 1.3 × 1011-7.9 × 1011) platelets compared with 5.6 × 1011 (range 2.6 × 1011-12.5 × 1011) or 11.0 × 1011 (range 7.1 × 1011-18.3 × 1011) in donors treated with 1 µg/kg or 3 µg/kg PEG-rHuMGDF, respectively. Substandard collections (<3 × 1011 platelets) were obtained from 26%, 4%, and 0% of the placebo, 1 µg/kg, and 3 µg/kg donors, respectively. No serious adverse events were reported; nor were there events that met the criteria for dose-limiting toxicity. Thrombopoietin therapy can increase platelet counts in healthy donors to provide a median 3-fold more apheresis platelets compared with untreated donors. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Thrombopoietin in healthy donors Robert M. Verdijk ;, David J. Kuter, and Lawrence T. Goodnough Blood 2002 99: 3867-3868. [Full Text] [PDF] This article has been cited by other articles: D. J. Kuter New thrombopoietic growth factors Blood, June 1, 2007; 109(11): 4607 - 4616. [Abstract] [Full Text] [PDF] M. Drouet, F. Mourcin, N. Grenier, V. Leroux, J. Denis, J.-F. Mayol, P. Thullier, J.-J. Lataillade, and F. Herodin Single administration of stem cell factor, FLT-3 ligand, megakaryocyte growth and development factor, and interleukin-3 in combination soon after irradiation prevents nonhuman primates from myelosuppression: long-term follow-up of hematopoiesis Blood, February 1, 2004; 103(3): 878 - 885. [Abstract] [Full Text] [PDF] F. Herodin, P. Bourin, J.-F. Mayol, J.-J. Lataillade, and M. Drouet Short-term injection of antiapoptotic cytokine combinations soon after lethal gamma -irradiation promotes survival Blood, April 1, 2003; 101(7): 2609 - 2616. [Abstract] [Full Text] [PDF] D. J. Kuter and C. G. Begley Recombinant human thrombopoietin: basic biology and evaluation of clinical studies Blood, November 15, 2002; 100(10): 3457 - 3469. [Abstract] [Full Text] [PDF] I. C. Haznedaroglu, H. Goker, M. Turgut, Y. Buyukasik, and M. Benekli Thrombopoietin as a Drug: Biologic Expectations, Clinical Realities, and Future Directions Clinical and Applied Thrombosis/Hemostasis, July 1, 2002; 8(3): 193 - 212. [Abstract] [PDF] S. Nomura, K. Dan, T. Hotta, K. Fujimura, and Y. Ikeda Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura Blood, June 28, 2002; 100(2): 728 - 730. [Abstract] [Full Text] [PDF] R. M. Verdijk ;, D. J. Kuter, and L. T. Goodnough Thrombopoietin in healthy donors Blood, May 15, 2002; 99(10): 3867 - 3868. [Full Text] [PDF] J. Li, C. Yang, Y. Xia, A. Bertino, J. Glaspy, M. Roberts, and D. J. Kuter Thrombocytopenia caused by the development of antibodies to thrombopoietin Blood, December 1, 2001; 98(12): 3241 - 3248. [Abstract] [Full Text] [PDF] L. T. Goodnough, D. J. Kuter, J. McCullough, S. J. Slichter, J. DiPersio, J. Romo, R. Peterson, K. J. Smith, T. Raife, D. Tomita, et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin Blood, September 1, 2001; 98(5): 1346 - 1351. [Abstract] [Full Text] [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020